anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention provides modified heparin binding growth factors (HBGFs). In particular, this invention provides a modified HBGF-1, an angiogenic polypeptide mitogen for mesoderm- and neuroectoderm-derived cells in vitro, that remains biologically active after deletion of the NH2-terminal domain (1-20;  alpha ) of the HBGF-1 beta  precursor. Using polymerase chain reaction mutagenesis and prokaryotic expression systems, a mutant of HBGF-1 alpha  lacking the nuclear translocation sequence, residues 21-27 (NYKKPKL; HBGF-1U) was prepared. HBGF-1U, like HBGF-1 alpha , binds to heparin, induces intracellular receptor-mediated tyrosine phosphorylation and the expression of the c-fos mRNA transcript, HBGF-1U does not stimulate DNA synthesis or cell proliferation. This invention also provides chimeric proteins in which the biological activity of the HBGF family member has been reconstituted. In particular, this invention provides a chimeric protein, HBGF-1U2, which contains HBGF 1U and the well-known histone 2B NTS sequence, GKKRKSKAK, at the amino-terminus. HBGF-1U2 has full mitogenic activity restored. This invention, thus, provides HBGF peptides that lack mitogenic activity and means to restore this activity. In addition, this invention provides peptides, HBGF-1U, that can be used as an antagonist of HBGF-1 function, particularly during events involving angiogenesis in vivo. Finally, this invention provides a method of treating diseases that involve pathological proliferation of endothelial cells, such as cancer, psoriasis, and arthritis.
The enrolled patients will receive 3 cycles of FLOT regimen +Toripalimab treatment before surgery, and every 2 weeks is a treatment cycle (Q2W). After completing the 3 cycles of treatment, the patient undergoes surgical resection.Toripalimab combined with FLOT regimen were maintained for 4 cycles after surgery.
The plant microbiome and plant-associated bacteria are known to support plant health, but there are limited studies on seed and seedling microbiome to reveal how seed-associated bacteria may confer disease resistance. In this study, the application of antibiotics on soybean seedlings indicated that seed-associated bacteria were involved in the seed rot resistance against a soil-borne pathogen Calonectria ilicicola, but this resistance cannot be carried to withstand root rot. Using PacBio 16S rRNA gene full-length sequencing and microbiome analyses, 14 amplicon sequence variants (ASVs) including 2 ASVs matching to Bacillus altitudinis were found to be more abundant in the four most resistant varieties versus the four most susceptible varieties. Culture-dependent isolation obtained two B. altitudinis isolates that both exhibit antagonistic capability against six fungal pathogens. Application of B. altitudinis on the most resistant and susceptible soybean varieties revealed different colonization compatibility, and the seed rot resistance was restored in the five varieties showing higher bacterial colonization. Moreover, quantitative PCR confirmed the persistence of B. altitudinis on apical shoots till 21 days post-inoculation (dpi), but 9 dpi on roots of the resistant variety TN5. As for the susceptible variety HC, the persistence of B. altitudinis was only detected before 6 dpi on both shoots and roots. The short-term colonization of B. altitudinis on roots may explain the absence of root rot resistance. Collectively, this study advances the insight of B. altitudinis conferring soybean seed rot resistance and highlights the importance of considering bacterial compatibility with plant varieties and colonization persistence on plant tissues.
BACKGROUND AND AIMS: Colorectal cancer (CRC) is the third most prevalent cancer globally, posing a significant challenge due to its high rate of metastasis. Approximately 20% of patients with CRC present with distant metastases at diagnosis, and over 50% develop metastases within five years. Accurate prediction of metastasis is crucial for improving survival outcomes in patients with CRC.
METHODS: This study introduces an innovative cost-sensitive fast correlation-based filter (CS-FCBF) algorithm for feature selection, integrated with machine learning techniques to predict metastatic CRC. The CS-FCBF algorithm effectively reduced the number of genomic features from 184 to 9 critical genes: CXCL9, C2CD4B, RGCC, GFI1, BEX2, CXCL3, FOXQ1, PBK, and PLAG1. The methodology combined in vitro, in vivo, and analysis of publicly available single-cell RNA-seq datasets to validate the findings.
RESULTS: The application of the CS-FCBF algorithm led to a significant improvement in prediction model performance, with an average 21.16% increase in the area under the precision-recall curve. The nine identified genes hold potential as diagnostic biomarkers and therapeutic targets for metastatic CRC.
CONCLUSIONS: This study highlights the critical role of advanced feature selection methods, combined with machine learning, in addressing the challenge of class imbalance in medical diagnosis, particularly for CRC. Early detection of metastasis is vital, and the identified genes underscore their importance in the metastatic process of CRC. The methodology applied here offers valuable insights and paves the way for future research in other cancers or diseases that face similar diagnostic challenges.
After completion of the 3-month DB phase, all eligible participants were offered the opportunity to enter an open-label LTSE for up to 96 months beginning at 10 mg OCA. Doses up to 50 mg daily were evaluated.
Cardiac safety regulatory guidance for drug development has undergone several monumental shifts over the past decade as technological advancements, analysis models and study best practices have transformed this landscape. Once, clinical proarrhythmic risk assessment of a new chemical entity (NCE) was nearly exclusively evaluated in a dedicated thorough QT (TQT) study. However, since the introduction of the International Council for Harmonisation (ICH) E14/S7B Q&A 5.1 and 6.1 TQT substitutions, drug developers are offered an alternative pathway to evaluate proarrhythmic risk during an ascending dose study in healthy volunteers or during a powered patient study, respectively. In addition, the findings as well as the manner in which nonclinical studies are conducted (i.e., utilizing best practices) can dictate the need for a positive control in the clinical study and/or affect the labeling outcome. Drug sponsors are now faced with the option of pursuing a dedicated TQT study or requesting a TQT substitution. Potential factors influencing the choice of pathway include the NCE mechanism of action, pharmacokinetic properties, and safety profile, as well as business considerations. This tutorial will highlight the regulatory framework for integrated arrhythmia risk prediction models to outline drug safety, delineate potential reasons why a TQT substitution request may be rejected and discuss when a standalone TQT is recommended.
BACKGROUND: CNP (C-type natriuretic peptide), an endogenous short peptide in the natriuretic peptide family, has emerged as an important regulator to govern vascular homeostasis. However, its role in the development of atherosclerosis remains unclear. This study aimed to investigate the impact of CNP on the progression of atherosclerotic plaques and elucidate its underlying mechanisms.
METHODS: Plasma CNP levels were measured in patients with acute coronary syndrome. The potential atheroprotective role of CNP was evaluated in apolipoprotein E-deficient (ApoE-/-) mice through CNP supplementation via osmotic pumps, genetic overexpression, or LCZ696 administration. Various functional experiments involving CNP treatment were performed on primary macrophages derived from wild-type and CD36 (cluster of differentiation 36) knockout mice. Proteomics and multiple biochemical analyses were conducted to unravel the underlying mechanism.
RESULTS: We observed a negative correlation between plasma CNP concentration and the burden of coronary atherosclerosis in patients. In early atherosclerotic plaques, CNP predominantly accumulated in macrophages but significantly decreased in advanced plaques. Supplementing CNP via osmotic pumps or genetic overexpression ameliorated atherosclerotic plaque formation and enhanced plaque stability in ApoE-/- mice. CNP promoted an anti-inflammatory macrophage phenotype and efferocytosis and reduced foam cell formation and necroptosis. Mechanistically, we found that CNP could accelerate HIF-1α (hypoxia-inducible factor 1-alpha) degradation in macrophages by enhancing the interaction between PHD (prolyl hydroxylase domain-containing protein) 2 and HIF-1α. Furthermore, we observed that CD36 bound to CNP and mediated its endocytosis in macrophages. Moreover, we demonstrated that the administration of LCZ696, an orally bioavailable drug recently approved for treating chronic heart failure with reduced ejection fraction, could amplify the bioactivity of CNP and ameliorate atherosclerotic plaque formation.
CONCLUSIONS: Our study reveals that CNP enhanced plaque stability and alleviated macrophage inflammatory responses by promoting HIF-1α degradation, suggesting a novel atheroprotective role of CNP. Enhancing CNP bioactivity may offer a novel pharmacological strategy for treating related diseases.
Written informed consent has to be obtained from 9 random female Caucasian patients aged between 40 and 80 years who will receive a Peeling assisted volume enhancing (PAVE) facelift procedure in Ocean Clinic, Marbella Spain, to take part in the histologic case control study with a within-subjects design.

After completing the facelift, the subcutaneous undermined abundant pre-auricular skin of both sides which is to be resected as consequence of the lift anyhow of each study patient is not resected and split completely in half to yield four samples of the same size, two on each side, without contacting each other in order to prevent any interaction between the peeling agents (n=9 samples per treatment). One sample serves as the control, while the other three samples are each treated with different peeling agents by the same surgeon: Trichloroacetic acid (TCA) peel at concentrations of 20% and 40% and a phenol/croton oil peel. The TCA samples are peeled immediately for 2 to 4 minutes until even frosting and neutralized at the even frosting point. The phenol/croton oil peeled samples are occluded with silicone tape for 24 hours and not neutralized. After 24 hours during the routine in-hospital stay of the patient, the skin samples are resected, the preauricular wound is closed, and all samples are placed in 10 % neutral buffered formalin. The samples are immediately processed, trimmed, embedded, sectioned and stained with haematoxylin and eosin (H\&E) by the same researcher. Histological evaluation which will take place in Tuebingen is carried out using a microscope, and pictures are captured at 10x, 25x and 100x magnification using a digital camera. Two trained histological examiners blinded to the study design independently perform histological evaluations. The depth of necrosis in µm is determined by analysing the tissue damage in relation to histological skin layers. All slices are evaluated using light microscopy to assess the mean depth of necrosis in three samples at three different sites for each specimen. The vertical height in µm between the cutaneous basal membrane and the deepest penetration of tissue damage is measured as well as the total thickness of the epidermis and dermis. Based on the histomorphological changes, actual peeling depth is determined and classified analogously to the current classification of burns: superficial, superficial-partial, deep-partial and full thickness.
Recurrence rates following surgical management of chronic subdural haematoma (CSDH) range from 5 to 33 %. There is growing evidence which suggests middle meningeal artery embolisation (MMAe) may reduce recurrence rates when used as surgical adjunct or standalone treatment. In this study we described our experience of this new procedure in the our UK institution. Patients with recurrent CSDH or CSDH at high risk of recurrence were selected for MMAe on a case-by-case basis following MDT discussion. A departmental database was used to identify patients treated. 26 CSDH were embolised in 20 patients; 9 CSDH were de-novo and 17 were recurrent. 10/26 CSDH were treated with MMAe only. No procedural mortality, access site or thrombo-embolic complications occurred. One patient experienced symptomatic collection growth 12 h following MMAe and required surgical drainage. 15 (75 %) of patients were living at home at follow-up (mean 14 months). On imaging follow-up 15/18 showed CSDH volume reduction or resolution, 1/18 remained stable requiring no further treatment, 2/18 patients suffered recurrent CSDH requiring treatment. In both recurrent cases incomplete embolisation was noted on procedural imaging (posterior division of MMA not embolised). Persistent posterior MMA division filling was significantly associated with collection recurrence (p = 0.002). Our results suggest MMAe as a stand-alone or adjuvant therapy can be performed safely in a UK neuroscience setting and is associated with high rates of symptomatic CSDH size reduction or resolution in problematic CSDH that have either recurred or are prone to recurrence.
The active ingredient in Gabapentin Oral Solution is gabapentin, which has the chemical name 1-(aminomethyl) cyclohexaneacetic acid.

The molecular formula of gabapentin is C 9H 17NO 2and the molecular weight is 171.24. The structural formula of gabapentin is: 

Gabapentin is a white to off-white crystalline solid with a pK a1of 3.7 and a pK a2of 10.7. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is -1.25. 

Gabapentin Oral Solution contains 250 mg of gabapentin per 5 mL (50 mg per mL) and the following inactive ingredients: artificial cool strawberry anise flavor, d-xylitol, glacial acetic acid, glycerin, purified water, and sodium acetate. Glacial acetic acid and/or sodium acetate used to adjust pH.
The surgical procedure in group B consisted of the placement of a 6.4cm diameter circular prosthesis (BARD Hernia Patch) at the intra-abdominal level. Subsequently, the liquid contained in the 10 ml opaque vial (AGHO solution) was administered according to randomization.
The invention provides a Chinese herbal medicine extract, a Chinese herbal medicine shampoo, a preparation method and an application of the Chinese herbal medicine extract and the Chinese herbal medicine shampoo. The preparation method of the Chinese herbal medicine extract comprises the following steps: taking 15-25 parts by weight of rhubarb root, 25-35 parts by weight of sweet wormwood herb, 15-25 parts by weight of cocklebur fruit, 25-35 parts by weight of polygonum multiflorum, 3-10 parts by weight of lucid ganoderma and 25-35 parts by weight of feline ginger as raw materials, and extracting the raw materials to obtain the Chinese herbal medicine extract. The preparation method of the shampoo comprises the following steps: mixing the above extracts with surfactant to obtain Chinese medicinal shampoo. The shampoo can comprise shampoo prepared by the method. The application comprises the application in the preparation of medicines for treating pruritic skin diseases or psoriasis and the application in the preparation of hair-blacking and/or hair-growing products. The beneficial effects of the invention can include: the preparation method is simple and convenient and has low cost; the product has the functions of growing hair, blackening hair, removing dandruff and relieving itching, and also has obvious effects on pruritic dermatosis and dermatophytosis.
PROBLEM TO BE SOLVED: To provide a method of screening out a renal disease therapeutic or prophylactic drug which exhibits a new mechanism of action by assaying the potentiation of a test sample on the expression of a fatty acid-binding protein in a zooblast, e.g. proximal tubular cell or the like. SOLUTION: On a method of screening out or identifying a renal disease therapeutic or prophylactic drug by means of assaying the potentiation of a test sample on the expression of a fatty acid-binding protein comprising a liver type fatty acid-binding protein or the like in a zooblast, e.g. renal proximal tubular cell or the like, the zooblast is cultivated in the presence or absence of the test sample, the expression amount of the fatty acid-binding protein in the zooblast is determined and further the expression amount in the presence of the test sample is compared with the expression amount in the absence of the test sample. By this method, the therapeutic or prophylactic drug for renal disease, e.g. diabetic nephropathy, glomerular nephritis, nephrotic syndrome, lupus nephritis, drug nephropathy and renal insufficiency or the like, is screened out.
PURPOSE:The titled composition, obtained by incorporating polymethyl methacrylate with a styrene-butadiene based thermoplastic elastomer or a hydrogenation product thereof dissolved in methyl methacrylate monomer, and having plasticity and shaping property. CONSTITUTION:A dental acrylic resin composition obtained by dissolving (B) 0.1-1pts.wt. styrene-butadiene thermoplastic elastomer or a hydrogenation product thereof in (A) 1pts.wt. liquid monomer of methyl methacrylate, and incorporating (C) 0.2-3pts.wt. polymethyl methacrylate in the resultant solution. Block copolymers of styrene-butadiene-styrene or styrene-isoprene-styrene are preferred for the component (B). The above-mentioned composition is a paste easily deformed by external pressure and has shaping properties of not easily deformed by the own weight thereof at the same time. Thus, the composition is polymerized and cured while keeping the shape in the injection. The composition is directly raised on a model of a jaw, and a denture with a base can be manufactured.
BACKGROUND: This study aimed to compare radiological features and short-term clinical outcomes between open-wedge high tibial osteotomy (OWHTO) and tibial condylar valgus osteotomy (TCVO), to provide information facilitating decision-making regarding those two procedures.
METHODS: Twenty-seven cases involving 30 knees that had undergone OWHTO (HTO group) and eighteen cases involving 19 knees that had undergone TCVO (TCVO group) for medial compartment knee osteoarthritis (OA) were retrospectively evaluated. Patient characteristics, severity of knee OA, lower limb alignment, joint congruity and instability were measured from standing full-length leg and knee radiographs obtained before and 1 year after surgery. Range of motion in the knee joint was measured and Knee Injury and Osteoarthritis Outcome Score (KOOS) was obtained to evaluate clinical results preoperatively and 1 year postoperatively.
RESULTS: Mean age was significantly higher in the TCVO group than in the HTO group. Radiological features in the TCVO group included greater frequencies of advanced knee OA, varus lower limb malalignment, higher joint line convergence angle, and varus-valgus joint instability compared to the HTO group before surgery. However, alignment of the lower limb and joint instability improved to comparable levels after surgery in both groups. Maximum flexion angles were significantly lower in the TCVO group than in the HTO group both pre- and postoperatively. Mean values in all KOOS subscales recovered similarly after surgery in both groups, although postoperative scores on three subscales (Symptom, Pain, and ADL) were lower in the TCVO group (Symptom: HTO, 79.0; TCVO, 67.5; Pain: HTO, 80.5; TCVO, 71.1; ADL: HTO, 86.9; TCVO, 78.0).
CONCLUSIONS: Both osteotomy procedures improved short-term clinical outcomes postoperatively. TCVO appears preferable in cases of advanced knee OA with incongruity and high varus-valgus joint instability. An appropriate choice of osteotomy procedure is important to obtain favorable clinical outcomes.
This clinical trial targets patients aged 60 years or older with American Society of Anesthesiologists physical status (ASA) 1 to 3 who undergo surgery under general anesthesia at our hospital. Before entering the operating room, patients are randomly assigned to the intravenous anesthesia group and the inhalation gas anesthesia group. The intravenous anesthesia group uses propofol for anesthesia, and the inhalation gas anesthesia group uses sevoflurane. A 3 mL blood sample is collected four times: before surgery, at the end of surgery, 4 hours after surgery, and 1st day after surgery. All blood samples will be immediately transferred to the department of Laboratory medicine and stored at -80 degree. Pre-scheduled tests to determine the brain-blood barrier permeability and inflammatory cytokines will be conducted after the recruitment of all samples. In addition, for patients scheduled to be transferred to the intensive care unit (ICU) after surgery among the study subjects, a 3 mL of cerebrospinal fluid sample is collected two times: before surgery, and at the end of surgery. The same preservation protocol will be applied to the cerebrospinal fluid samples. All study subjects will be monitored for postoperative delirium daily for up to 7 days after surgery or until discharge. Cognitive function is assessed using telephone version of the Montreal Cognitive Assessment (T-MOCA) before surgery and 3 months after surgery.
Heterotopic ossification (HO) is defined as 'bone where it does not belong'. Given the historical variety of nomenclature and eponyms, there is significant confusion about the etiology, pathogenesis, classification, and treatment of HO related to the temporomandibular joint (TMJ). The existing classifications for TMJ HO have shortcomings: they relate to specific populations, use differing imaging studies and demographic data, do not universally include alloplastic/autologous replacements, are based variously on radiological and/or clinical presentations that cannot always be combined, and were largely developed to assist oral and maxillofacial surgeons in surgical management. These deficiencies make it problematic to compare studies, draw valid conclusions, and pursue research. The aim of this study was to develop a new, more inclusive classification for TMJ HO. Currently available classifications were evaluated and a Delphi-type system used to build consensus from clinicians and researchers to develop a new system. Fourteen unique classifications for TMJ ankylosis/HO were identified. In light of the biological specifics related to heterotopic calcification of extracellular matrix versus heterotopic formation of actual bone, the group recommends a more unambiguous term - peri-articular bone formation - and proposes a new classification. This will help clinicians and researchers to study, describe, and manage various types of ectopic bone associated with the TMJ.
Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
The control group underwent treatment throughout a 6-month period, directed by each patient's medical practitioner. This consisted of the patients carrying out regular weekly general exercises (walking and swimming). Three of them regularly attended other treatment providers involving group general exercise programs. Two patients received the application of local pain-relieving methods such as heat, massage, laser and ultrasound and one did nothing except for receiving osteoporotic medication.